Filing Flows › Arcutis Biotherapeutics (ARQT) › ZORYVE foam revenue
Arcutis Biotherapeutics (ARQT) ZORYVE foam revenue by quarter
Arcutis Biotherapeutics' ZORYVE foam revenue was $75.1M in Q3 2026 (third quarter 2026), +12% from Q2 2026. Over the last 6 quarters it ranged from $30.2M (Q1 2025) to $75.1M (Q3 2026).
| Quarter | ZORYVE foam revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $75.1M | +12% | +51% |
| Q2 2026 | $67.4M | +36% | +72% |
| Q1 2026 | $49.6M | -0.3% | +64% |
| Q3 2025 | $49.8M | +27% | — |
| Q2 2025 | $39.2M | +30% | — |
| Q1 2025 | $30.2M | — | — |
Q3 2026 at a glance
Arcutis Biotherapeutics, Q3 2026: revenue $144M (+45% year over year), operating margin 6.6%, net earnings $8.8M, operating cash flow $18.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Arcutis Biotherapeutics' ZORYVE foam revenue?
Arcutis Biotherapeutics' ZORYVE foam revenue was $75.1M in Q3 2026 (third quarter 2026), +12% from Q2 2026.
How has Arcutis Biotherapeutics' ZORYVE foam revenue changed?
Over the last 6 quarters it ranged from $30.2M (Q1 2025) to $75.1M (Q3 2026).
Q3 2026 results → · How Arcutis Biotherapeutics makes money →